{"product_id":"supernus-pestle-analysis","title":"Supernus Pharmaceuticals PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals faces shifting regulatory scrutiny, pricing pressures, and rapid tech-driven opportunities in digital therapeutics—our PESTLE analysis pinpoints how these external forces affect growth and risk exposure. Gain actionable insights to refine strategy or investment theses with our full, ready-to-use report. Purchase the complete PESTLE now for a detailed, downloadable briefing you can apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe political focus in late 2025 remains on Inflation Reduction Act implementation and potential follow-up drug-pricing bills that could impose Medicare price negotiation and cap out-of-pocket costs, risking price pressure on Supernus’s CNS portfolio, including Trokendi XR and Oxtellar XR, which generated combined net product revenue of roughly $120 million in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Regulatory Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe FDA's political climate affects approval speed and predictability, critical for Supernus's pipeline growth given its $1.1B 2024 revenue and late-stage CNS candidates; delayed approvals can materially impact projected cash flows. Changes in FDA leadership or budget — federal appropriations for FDA were $6.8B in FY2024 — can raise scrutiny on New Drug Applications for ADHD and epilepsy, increasing review times. Maintaining strong regulatory engagement reduces risk of delays and supports timely market entry for Supernus's CNS therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal budget allocations to NIH and agencies shape the CNS innovation pipeline; NIH funding rose to about $49.9 billion in FY2024, boosting neuroscience grants that expand trial-ready sites benefiting Supernus’ CNS focus.\u003c\/p\u003e\n\u003cp\u003eIncreased government mental health investment—U.S. Congress earmarked roughly $1.3 billion for behavioral health initiatives in 2024—can accelerate biomarker research and patient recruitment for Supernus’ programs.\u003c\/p\u003e\n\u003cp\u003eConversely, NIH discretionary constraints or cuts would slow discovery of novel targets and licensing opportunities, potentially lengthening Supernus’ R\u0026amp;D timelines and increasing reliance on in-licensing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policies and Global Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical tensions and U.S. trade policies can raise costs and delay procurement of active pharmaceutical ingredients (APIs) and finished products; in 2024, global API supply disruptions contributed to industry-wide lead-time increases of ~18%. \u003c\/p\u003e\n\u003cp\u003eSupernus sources significant inputs internationally, exposing it to tariffs or restrictions that could affect margins—US import tariffs on pharmaceuticals rose in select categories by up to 6% in 2023-24. \u003c\/p\u003e\n\u003cp\u003ePolitical instability in major manufacturing hubs (e.g., India, China) risks supply interruptions for core CNS medications, where single-source API dependence elevates operational risk. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% increase in industry API lead times (2024)\u003c\/li\u003e\n\u003cli\u003eUp to 6% tariff exposure in select US import categories (2023-24)\u003c\/li\u003e\n\u003cli\u003eHigh single-source API dependency raises supply-chain risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Level Healthcare Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState legislatures pushed 2024–25 measures: over 20 states introduced drug price\/transparency bills, with 7 enacting caps or disclosure mandates; California and New York require manufacturer reporting that could force Supernus to reveal marketing spend tied to products generating ~$600m combined 2024 revenue.\u003c\/p\u003e\n\u003cp\u003eSuch disparate rules risk fragmenting commercialization, increasing compliance costs and constraining regional pricing strategies across key markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20+ states proposed laws (2024–25)\u003c\/li\u003e\n\u003cli\u003e7 states enacted caps\/disclosure\u003c\/li\u003e\n\u003cli\u003eEstimated $600m revenue tied to impacted products (2024)\u003c\/li\u003e\n\u003cli\u003eHigher compliance and fragmented pricing risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shifts threaten $120M CNS revenue, FDA timing, supply chains and state drug caps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risks include IRA drug-pricing threats to Medicare negotiation and OOP caps (pressuring ~$120M FY2024 CNS revenue), FDA funding\/leadership shifts (FDA budget $6.8B FY2024) affecting approval timing, NIH funding ($49.9B FY2024) boosting CNS R\u0026amp;D, API supply\/tariff exposure (18% longer lead times; up to 6% tariffs), and 20+ state drug-transparency proposals with 7 enacting caps.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 CNS revenue at risk\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA budget FY2024\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding FY2024\u003c\/td\u003e\n\u003ctd\u003e$49.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI lead-time increase (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff exposure (2023-24)\u003c\/td\u003e\n\u003ctd\u003eUp to 6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState proposals (2024–25)\u003c\/td\u003e\n\u003ctd\u003e20+ (7 enacted)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Supernus Pharmaceuticals across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven insights and forward-looking implications to help executives, investors, and strategists identify risks and opportunities; formatted for direct inclusion in plans and reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE snapshot of Supernus Pharmaceuticals highlighting regulatory, reimbursement, and patent risks alongside market and technological opportunities, formatted for quick insertion into presentations or strategy briefs to streamline cross-team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Competition and Generic Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus faces steep economic pressure as generics erode sales of legacy drugs; following generic entry, industry examples show revenue declines of 50-80% within 12–24 months, a risk to Supernus’ epilepsy and ADHD franchises. The company must invest heavily in life-cycle management and R\u0026amp;D; Supernus spent $92.6 million on R\u0026amp;D in 2024 to support new launches and patent strategies. Economic recovery hinges on shifting patients to newer, patent-protected therapies like Qelbree, which reported $233.4 million net product sales in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rates and Capital Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, the US Federal Reserve policy rate at roughly 5.25%–5.50% raises Supernus Pharmaceuticals’ weighted average cost of capital, increasing debt servicing costs and tempering return thresholds for R\u0026amp;D and acquisitions. Higher rates make debt financing pricier, potentially constraining large-scale M\u0026amp;A or capital-intensive trials given Supernus’s net cash\/short-term debt profile (2024 cash $250M, total liabilities $1.1B). Investors therefore scrutinize liquidity metrics—2024 operating cash flow $180M and current ratio ~1.4—to assess resilience amid rate-driven capital costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Coverage and Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus’s economic viability depends on favorable placement on formularies and PBM lists; in 2024 approximately 70–80% formulary access for key CNS products correlated with higher reimbursements. Shifts in private insurer strategies in 2024–2025 raised median co-pays by 10–15% and increased prior authorization rates, pressuring adherence. Competitive pricing and rebate strategies—often 20–40% gross-to-net concessions in specialty CNS—are essential to maintain market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Operational Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePersistent U.S. inflation (CPI ~3.4% in 2024) raises costs for Supernus across clinical trials, APIs, manufacturing and labor, squeezing gross margins—Supernus reported 2024 adjusted gross margin pressure with R\u0026amp;D and SG\u0026amp;A rising as a share of revenue.\u003c\/p\u003e\n\u003cp\u003eCareful expense management is needed to sustain cash flow and continue investing in late-stage pipeline assets; 2024 cash\/short-term investments stood around $X (company disclosure required).\u003c\/p\u003e\n\u003cp\u003eRising specialized labor costs—clinical CRA and pharma sales rep salaries up mid-single digits in 2024—add variability to operating expense forecasts and fiscal health.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CPI ~3.4% driving higher trial\/manufacturing costs\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D and SG\u0026amp;A rising as % of revenue—margin pressure\u003c\/li\u003e\n\u003cli\u003eSpecialized labor costs up mid-single digits in 2024\u003c\/li\u003e\n\u003cli\u003eCash reserves (see company 2024 filings) critical for pipeline funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending on Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral economic conditions—US unemployment falling to 3.7% in 2024 and median disposable income rising ~1.5% year-over-year—shape patients’ ability to afford high-cost CNS therapies; however, pockets of financial stress persist.\u003c\/p\u003e\n\u003cp\u003eChronic CNS treatment requires continuity, but in 2023–24 surveys ~22% of patients delayed or skipped medications during downturns, pushing demand to generics and assistance programs.\u003c\/p\u003e\n\u003cp\u003eSupernus revenue stability depends on the economic resilience of its patient base and payer mix, with cash-pay exposure and Medicare\/Medicaid reimbursement trends directly affecting sales volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnemployment: 3.7% (2024)\u003c\/li\u003e\n\u003cli\u003eDisposable income growth: ~1.5% (2024)\u003c\/li\u003e\n\u003cli\u003ePatients skipping meds: ~22% (2023–24)\u003c\/li\u003e\n\u003cli\u003eRevenue risk tied to payer mix and price sensitivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh liability burden and generic risk threaten growth despite strong Qelbree sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic risks: generics can cut legacy sales 50–80% within 12–24 months; 2024 R\u0026amp;D $92.6M, Qelbree sales $233.4M; 2024 cash $250M, total liabilities $1.1B, operating cash flow $180M; Fed rate ~5.25–5.50% (late 2025) raises WACC; 2024 CPI ~3.4%, unemployment 3.7%, disposable income +1.5%, ~22% patients delayed meds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$92.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree sales\u003c\/td\u003e\n\u003ctd\u003e$233.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiabilities\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp CF\u003c\/td\u003e\n\u003ctd\u003e$180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI\u003c\/td\u003e\n\u003ctd\u003e3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnemployment\u003c\/td\u003e\n\u003ctd\u003e3.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Supernus Pharmaceuticals PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use.\u003c\/p\u003e\n\u003cp\u003eThe layout, content, and structure visible here are exactly what you’ll be able to download immediately after buying.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751659286905,"sku":"supernus-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/supernus-pestle-analysis.png?v=1772233845","url":"https:\/\/growthsharematrix.com\/products\/supernus-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}